U.S. approves Moderna, Pfizer's new crown vaccine for emergency use in people 6 months and older

U.S. Food and Drug Administration. Xinhua News Agency

On the 17th, the US Food and Drug Administration revised the emergency use authorization for the new crown vaccine developed by the US biotechnology company Moderna and the new crown vaccine jointly developed by the US Pfizer and German biotechnology companies, and approved the use of these two vaccines in People aged 6 months and above.
According to the latest revision of the US Food and Drug Administration, the Moderna vaccine is used in two doses of 6 months to 17 years old, with an interval of 1 month; the Pfizer vaccine is used in 6 months to 4 years old in 3 doses, the first two doses The third dose is at least 8 weeks apart from the second dose 3 weeks apart.
The FDA previously approved the Moderna vaccine for use in people 18 and older, and the Pfizer vaccine for use in people 5 and older.
The FDA said in a statement that approval of the authorization was based on a rigorous and comprehensive evaluation and analysis of the safety, efficacy and manufacturing data of the two vaccines. The FDA believes that the known and potential benefits of the two vaccines in approved children outweigh their known and potential risks. The FDA consulted its independent panel of experts before making its decision.
FDA Commissioner Robert Califf said in a statement that he hopes that the approval of the new crown vaccine for young children will protect this age group from serious consequences of the new crown, including hospitalization, death and so on.
(Originally titled "US FDA Approves Moderna, Pfizer's New Crown Vaccines for Emergency Use in People 6 Months and Over")